J.-L. Lee
Impact in
-
- Renal cell carcinoma treatment
- Gastric Cancer Management and Outcomes
-
- Cancer Genomics and Diagnostics
Papers in
-
- Renal cell carcinoma treatment 5
- Gastric Cancer Management and Outcomes 1
- Oncology 3
- Cancer Immunotherapy and Biomarkers 2
- CAR-T cell therapy research 1
- Co-authors
- Cheryn Song (2 shared papers)Jun Hyuk Hong (2 shared papers)Daniel Peter Petrylak (2 shared papers)Christof Vulsteke (1 shared paper)Daniel Castellano (1 shared paper)Chunzhang Wu (1 shared paper)Mary Scott Campbell (1 shared paper)Ronac Mamtani (1 shared paper)
- Journals
- Annals of Oncology (5 papers)Japanese Journal of Clinical Oncology (4 papers)ESMO Open (1 paper)
- Partner nations
- South KoreaUnited StatesFrance
In The Last Decade
J.-L. Lee
9 papers receiving 385 citations
J.-L. Lee's Hit Papers
Peers
Comparison fields: 5 of 39
- Pulmonary and Respiratory Medicine 199
- Cancer Research 53
- Oncology 92
- Surgery 102
- Hematology 15
Countries citing papers authored by J.-L. Lee
This map shows the geographic impact of J.-L. Lee's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J.-L. Lee with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J.-L. Lee more than expected).
Fields of papers citing papers by J.-L. Lee
This network shows the impact of papers produced by J.-L. Lee. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J.-L. Lee. The network helps show where J.-L. Lee may publish in the future.
Co-authors
The 25 scholars most cited alongside J.-L. Lee, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma Hit paper breakdown → | 2023 | 118 |
| 2 | 2012 | 87 | |
| 3 | 2010 | 84 | |
| 4 | 2007 | 37 | |
| 5 | 2004 | 29 | |
| 6 | 2008 | 13 | |
| 7 | 2019 | 10 | |
| 8 | 2019 | 9 | |
| 9 | 2021 | 6 | |
| 10 | 2016 | 0 |
About J.-L. Lee
J.-L. Lee is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Public Health, Environmental and Occupational Health, Genetics and Surgery, having authored 10 papers that have together received 393 indexed citations. Recurring topics across this work include Renal cell carcinoma treatment (5 papers), Cancer Immunotherapy and Biomarkers (2 papers), Bladder and Urothelial Cancer Treatments (2 papers), Renal and related cancers (1 paper), Gastric Cancer Management and Outcomes (1 paper), Esophageal Cancer Research and Treatment (1 paper), Palliative Care and End-of-Life Issues (1 paper) and CAR-T cell therapy research (1 paper). The work is most often cited by research in Pulmonary and Respiratory Medicine (199 citations), Cancer Research (53 citations), Oncology (92 citations), Surgery (102 citations) and Hematology (15 citations). J.-L. Lee has collaborated with scholars based in South Korea, United States and France. Frequent co-authors include Cheryn Song, Jun Hyuk Hong, Daniel Peter Petrylak, Christof Vulsteke, Daniel Castellano, Chunzhang Wu, Mary Scott Campbell, Ronac Mamtani, Nobuaki Matsubara and Ignacio Durán. Their work appears in journals such as Annals of Oncology, Japanese Journal of Clinical Oncology and ESMO Open.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.